Ruolo dei nuovi farmaci nel tumore del polmone

In recent years, the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) have been recognized as a central players and regulators of cancer cell proliferation, apoptosis and angiogenesis and, therefore, as a potentially relevant therapeutic target. Several strategies for EGFR and VEGF targeting have been developed, the most successful being represented by monoclonal antibodies (MAbs), that directly interfere with ligand-receptor binding and small molecule tyrosine kinase inhibitors (TKIs), that interfere with activation/phophorylation of EGFR and VEGF. These agents have been authorized in advanced cancers, including , non small cell lung cancer (NSCLC)